Informed consent for schizophrenia research: what is an investigator (or IRB) to do?
Informed consent for schizophrenia research: what is an investigator (or IRB) to do?
复制标题
精神分裂症研究的知情同意:研究者(或 IRB)应该做什么?
DOI:
10.1002/bsl.695
复制
发表时间:
2006
影响因子:
1.4
通讯作者:
Palmer,BartonW
中科院分区:
文献类型:
--
作者:
Palmer,BartonW
Decisionmaking Capacity (NBAC, 1998). Reaction to this report catalyzed a growing body of empirical research on informed consent and decisional capacity in schizophrenia and other conditions. Some of the key points made in Dunn's (2006) outstanding review of this empirical literature include the following.(a) As a group, patients with schizophrenia tend to perform worse than healthy comparison subjects on measures of decisional capacity, particularly in terms of understanding of the disclosed information.(b) There is considerable within-group heterogeneity, such that diagnosis is clearly an inappropriate basis on which to conclude a person lacks adequate decisional capacity to give meaningful consent.(c) Cognitive deficits, more than severity of psychopathology, are the strongest predictors of impaired decisional capacity.(d) There have been substantial advances in the development of structured tools for assessment of decisional capacity, but further development of such tools is still needed.(e) Understanding of disclosed information may be improved through simple enhancements in the consent process, such as an interactive process of disclosure, query, and re-explanation, and/or structured presentation of key information.As Dunn notes, among other criticisms of the NBAC (1998) report, there has been general concern that the sole emphasis on" mental disorders" in the report risks further inappropriate stigmatization of those with psychiatric illness. In light of findings such as the above, it would be inappropriate to assume that those with schizophrenia, as a group, are incapable of giving meaningful consent or require unique protections.